ClinicalTrials.gg
Enrolling by invitationNCT03417856Updated Apr 27, 2026

Defining the Skin and Blood Biomarkers of Ichthyosis

An observational study in Ichthyosis and Netherton Syndrome, sponsored by Northwestern University. Enrolling by invitation at 4 sites in United States. Open to participants aged 1 Year to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Primary conditionNetherton SyndromeRegistry: IchthyosisReclassifiedWhy we changed it
Registry
Ichthyosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Netherton Syndrome
Why
  1. The study's listed conditions name Netherton Syndrome, a narrower term within Ichthyosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Northwestern University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
200
Ages
1 Year to 60 Years
Sex
All
01

Study summary

Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis.

Hypothesis: We predict that the biomarkers correlating with disease activity in Netherton syndrome will be different than the biomarkers found to correlate with the lamellar and other ichthyosis phenotype.

Read the detailed description

Objectives:

  1. To define a panel of skin and blood biomarkers associated with disease activity and pruritus in Netherton syndrome, lamellar ichthyosis, and other ichthyosis subtypes.
  2. To determine if blood samples can serve as surrogates for skin immune activation and will correlate with disease severity.
  3. To determine FLG, SPINK5, TGM1, or other mutation via buccal/saliva samples in ichthyosis subjects
  4. To determine differences in alterations of epidermal lipids and proteins in the outer stratum corneum of epidermis collected from tape strips in patients with ichthyosis compared to the general population. There will also be a difference detected in epidermal lipids from blood samples.
02

Conditions studied

  • Ichthyosis
  • Netherton Syndrome

Browse trials for

Keywords

  • Ichthyosis
  • Netherton Syndrome
03

In context

Netherton Syndrome Reclassified

22 studies on the registry are indexed under Netherton Syndrome; 5 are open to participants now.

Browse Netherton Syndrome studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,423 studies on the registry; 198 are open to participants now.

Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.

Compared within Netherton Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ichthyosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
1 Year to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

150 subjects (1 year to 60 years of age) with diagnosis of Netherton Syndrome or ichthyosis will be enrolled. Approximately 50 healthy controls will be enrolled. The blood sample, skin biopsy, and buccal/saliva sample may be obtained from the same ichthyosis subject. However there will be separate groups of control patients for the skin biopsies and blood sample studies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Control and ichthyosis subjects may be of either sex and must be between 1-60 years of age at the time of enrollment
  • Ichthyosis subjects include individuals with a diagnosis Netherton syndrome, lamellar ichthyosis, or other ichthyosis subtypes
  • Ichthyosis subjects should not have administered systemic therapy in the month before the study
  • Ichthyosis subjects should not use topical immunosuppressants in the week before the study
  • Ichthyosis subjects should not have applied emollients to the planned sites within 12 hours before biopsy, but can be applied elsewhere
  • Controls may have no inflammatory disease, atopy, or obvious xerosis (urticaria, food allergy, allergic rhinitis or conjunctivitis, asthma)
  • Controls for skin sampling may have no observable abnormality in the sampled skin and, to further assure the normality of the "normal" skin edges, must not have evidence of inflammation or epidermal change in the lesion to be surgically removed
  • Subjects and guardians of minors must sign the approved IRB consent form(s) prior to initiation of the study protocol

Exclusion criteria

Exclusion Criteria:

  • Subjects who are unable to give or assent
  • Subjects who administered anti-inflammatory systemic and topical therapy or emollients that do not comply with inclusion criteria prior to blood and sampling
  • Subjects whose main diagnosis is deemed unsafe by the study investigator for study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Control

    Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.

  • Ichthyosis

    Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.

06

What researchers measure

Primary outcomes

  1. Cellular infiltrates

    We will examine your skin and blood samples for various immune cells known to be involved in ichthyosis.

    Time frame: One year

  2. Gene expression

    We will examine your skin and blood samples for various genes known to contribute to ichthyosis by analyzing RNA and cytokines.

    Time frame: One year

Secondary outcomes

  1. Correlation of biomarkers to quality of life

    We will analyze the blood and tissue biomarkers to determine whether they are comparable to quality of life and itch (pruritus) measures.

    Time frame: One year

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Dec 2027, 119 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Jan 31, 2018
StartActual
Jan 31, 2018
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03417856
Responsible party
Amy Paller (Pediatric Dermatologist, Northwestern University) — Principal investigator
First posted
Jan 31, 2018
Start date
Jan 31, 2018
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion